COREE

What COREE does

Coree Limited (COREE) is a Eurasia-based healthcare group founded in 2008, with operational roots in Korea and a primary commercial footprint across China and broader Asia. The company operates as an integrated multi-vertical platform spanning five business lines: manufacturing, R&D, supply chain, branding, and social network. In China alone, it reaches 1,600+ distributors, 360,000+ pharmacies, 150,000+ clinics, and 10,064 offline branded stores across all 31 provinces, supported by 1,000+ employees including 823+ sales representatives.

Coree's core technology centers on microbiome science. It holds approximately 95 patents globally and maintains a proprietary strain library of 17 core microbiome strains, of which 5 are currently commercialized. Manufacturing is anchored by 8,000+ tons of annual capacity operating under HACCP and CNAS dual certification, with an additional Italian Research Center established in partnership with Gemelli Hospital to extend R&D beyond Asia. A disclosed 5-candidate R&D pipeline carries a stated combined development value exceeding $530M, indicating the company's product surface is in active expansion.

Revenue is generated across three principal streams: contract manufacturing and OEM for major F&B clients (Mengniu, Yili, Sanyuan); large-scale distribution services — anchored by a long-running partnership with Beijing Hanmi Pharmaceutical originating in 2007 and projected to handle RMB 1.905B in 2025 — and own-brand probiotics sold under the Ofmom label, which exceeds RMB 100M in annual sales on Douyin alone, supplemented by offline store and Korea-market expansion under Ofmom KR.

Name

COREE

Legal name

Coree Limited

Website

https://coree.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

Coree Limited is a Eurasia-based healthcare group operating integrated manufacturing, R&D, distribution, branding, and supply-chain verticals across Asia, leveraging 17 proprietary microbiome strains, 95+ patents, and a 31-province pharmacy network reaching 360,000+ outlets.

Ownership category

akta.pro rank

Product category

Contract Pharmaceutical Manufacturing

NAICS

Food Manufacturing (311), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Food And Kindred Products (2000)

akta.pro primary industry

Functional Baby & Kids Foods Manufacturing (Fortified Infant/Toddler Foods, Kids Nutrition) (AFAKAJAJ)

akta.pro secondary industry

Baby Feeding Supplements & Fortifiers (Probiotics, DHA/ARA, Vitamins) (CRADAEAI)

Keywords

• Contract pharmaceutical manufacturing
• Microbiome R&D licensing
• Pharmaceutical distribution services
• Nutritional supplement OEM
• Brand marketing services

Headquarters

HQ city

Gaithersburg

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. OEM/ODM Manufacturing: High-standard manufacturing and OEM solutions for infant formula, probiotics, and nutritional health products. Annual capacity 8,000+ tons with own-brand product output value of ¥8.582 million in 2025.
2. IP Licensing & R&D Pipeline Partnership: License Coree validated strains, formulas, or production processes for rapid productization. Strategic pipeline partnership, joint R&D, and equity investment in mature pipelines. 5 pipelines valued at $530M+.
3. Branding & Digital Marketing Services: End-to-end brand building and marketing services including brand strategy, digital marketing, design services, community platform operations, and integrated marketing. 3,000+ design projects delivered, 16 industry leading clients.
4. Distribution Agency: Omnichannel distribution network covering pharmaceutical distribution, maternal stores, supermarkets, and e-commerce. Distribution agency for exclusive or non-exclusive distribution. Pharmaceutical distribution RMB 1.745 billion in 2024, RMB 1.998 billion in 2025.
5. Digital Ecosystem Services: Social media operations, KOL/KOC marketing, content creation, media placement, and community operations services. Platform partnerships for ad placement and content collaboration.

Go-to-market motion5 records

Distribution channels7 records

Marketing channels9 records

Core offering

COREE delivers high-standard pharmaceutical-grade contract manufacturing and OEM solutions for infant formula, probiotics, and nutritional health products, supported by a microbiome R&D pipeline with IP licensing. It complements manufacturing with an omnichannel pharmaceutical distribution network spanning 31 Chinese provinces, plus end-to-end brand building, design outsourcing, and digital marketing services for healthcare and FMCG clients.

Product overview

COREE is a multi-vertical healthcare group operating five core business units: Manufacturing & OEM Solutions, R&D Pipeline & IP Licensing, Branding Services, Supply Chain & Distribution, and Social Network & Digital Engagement. The company manufactures its own Ofmom brand product line including infant formula, probiotics, children's growth milk powder, and nutritional supplements, while also offering contract manufacturing services. R&D operations span five microbiome and pharmaceutical pipelines (ImmuneBac Platform, HMO Alternative, Metabolic Disease Microbiome Therapeutics, Weaning Nutrition Therapy, and Herita) with 17 proprietary strains and 90+ patents. Service offerings include brand strategy and digital marketing, omnichannel distribution across 31 provinces in China, and digital ecosystem services for maternal and health communities.

Differentiator

Problem solved

Functional benefit

Brands

• Ofmom: Maternal & infant nutrition brand offering infant formula, probiotics, children's growth milk powder, and nutritional supplements
• Mamiai
• Ofmom Infant Formula Series
• Ofmom Probiotics Series
• Ofmom Children's Growth Milk Powder
• Ofmom Nutritional Supplements

Quantifiable outcome

• Ofmom probiotic sales ranked TOP6 on Douyin with annual sales exceeding RMB 100 million
• +5 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

16 partnerships are on record, tiered flagship and core.

• Beijing Hanmi PharmaceuticalflagshipChannel Partner/ Reseller/ Distributor · 1 January 2007Strategic partnership since 2007 for nationwide pharmaceutical distribution. Products include Medilac-Vita (household name for 30 years, multiple CPMC Brand Awards) and Ambroxol (200M+ cumulative pediatric doses). 2024 sales RMB 1.64 billion, 2025 sales RMB 1.905 billion. Services include market promotion, channel management, academic promotion, and SCSS digital clinic management system.
• Gemelli Hospital, RomecoreStrategic or Co-development PartnerClinical research collaboration platform supporting microbiome, metabolomics, and nutritional intervention studies. Led by Prof. Antonio Gasbarrini (National Coordinator of the Italian Society of Gastroenterology Gut Microbiota Study Group). Collaboration on Metabolic Disease Microbiome Therapeutics pipeline for Type 2 diabetes and obesity patients.
• Sichuan UniversitycoreStrategic or Co-development PartnerUniversity research partnership connecting strain discovery, functional validation, and nutrition science to Coree's broader R&D and commercialization pipeline. Collaboration on microemulsion vaccine delivery system patent.
• Heilongjiang Tianlong PharmaceuticalcoreChannel Partner/ Reseller/ DistributorDistribution partnership for Oral Inflammation Spray with cumulative sales RMB 413 million from 2020-2025. Successfully entered multiple tertiary hospitals with deep OTC retail penetration. Full-cycle services including hospital access, academic promotion, OTC retail expansion, and brand operations.
• CSGC Shantou Jinshi Pharmaceutical (Aiqi Mei)coreChannel Partner/ Reseller/ DistributorAzithromycin series partnership with 2023 custom packaging winning London Design Award Gold. Successfully pivoted to off-hospital market after VBP non-winning challenge, achieving stable annual sales of RMB 25M+ through private clinics, OTC pharmacies, and community medical centers.
• Coree WUHANcoreOthersAffiliated company - healthcare operations subsidiary
• Medi'CarecoreOthersAffiliated company - healthcare brand
• Dx&VxcoreOthersAffiliated company - health technology brand
• OfmomflagshipOthersFlagship own-brand covering infant formula, probiotics, and nutritional supplements with nationwide distribution. Ranked TOP6 on Douyin for probiotic sales, 10,064 offline store coverage, annual sales exceeding RMB 100 million.
• Hanmi PharmcoreChannel Partner/ Reseller/ DistributorPharmaceutical brand partnership for distribution of pharmaceutical products including Medilac-Vita and Ambroxol
• MengniucoreChannel Partner/ Reseller/ DistributorHigh-standard manufacturing partnership for infant formula and dairy products
• YilicoreChannel Partner/ Reseller/ DistributorHigh-standard manufacturing partnership for infant formula and dairy products
• SanyuancoreChannel Partner/ Reseller/ DistributorHigh-standard manufacturing partnership for dairy products
• Korea BiopharmcoreChannel Partner/ Reseller/ DistributorBrand full-service client for Korea Biopharm
• FescarocoreChannel Partner/ Reseller/ DistributorDigital ecosystem partnership for platform operations (brand official website, WeChat official account, WeChat video account, Bilibili) and content operations (Baidu Zhidao/Zhihu reputation building, media PR and distribution)
• MAMMS CLINIC PLASTIC SURGERYcoreChannel Partner/ Reseller/ DistributorPlatform operations partnership across WeChat, Weibo and Bilibili. Daily SNS content, KOC store visit promotions, and brand favorability content driving store conversion.

Scale indicators19 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Chr. Hansen: Global probiotics and microbiome science company with proprietary bacterial strain library and IP licensing model; directly comparable to Coree's 17-strain library, 5 microbiome pipelines ($530M+ value), and probiotic ingredient business targeting infant and metabolic health applications.
• Ausnutria Dairy: Hong Kong-listed infant formula and nutrition manufacturer with a major China go-to-market through pharmacy and maternal channels; directly comparable to Coree's Ofmom infant formula and OEM services for Mengniu/Yili/Sanyuan, with similar China-distribution-heavy business model.
• Beingmate Baby & Child Food: Chinese infant formula manufacturer with nationwide pharmacy and maternal-store distribution; closest direct competitor to Coree's Ofmom brand in China across infant nutrition, probiotic supplements, and kids' nutritional products.
• BlueFocus Intelligent Communications: China's leading digital marketing and brand-building services group; comparable to Coree's branding services vertical (3,000+ design projects, KOL/KOC marketing, content creation, full-platform SNS operations, and brand case studies for pharma/FMCG/health clients).
• Health and Happiness (H&H) International: Global infant nutrition and probiotics group (Biostime, Swisse Plus+) with significant China and Asia exposure; comparable to Coree's Ofmom infant formula, probiotics, and children's growth milk powder lines and to its omnichannel maternal & infant distribution model in China.

Others

• Mengniu Dairy: Coree's manufacturing partner; comparable in infant formula and dairy nutrition categories but operates as a leading brand owner rather than a platform/OEM provider; relevant for understanding competitive dynamics in infant formula supply chain where Coree provides OEM services.
• Yili Industrial Group: One of Coree's OEM/ODM manufacturing customers and a category-defining Chinese dairy and infant formula brand; adjacent rather than directly competitive, as Yili outsources certain production to Coree and competes in similar end markets.

Broad incumbents

• Sinopharm Group: Largest pharmaceutical distributor in China with nationwide hospital and pharmacy coverage; comparable to Coree's distribution vertical (1,600+ distributors, 360,000+ pharmacies, 150,000+ clinics) but at vastly larger scale and as a state-owned broad incumbent across all therapeutic areas rather than a focused consumer-health/pharma platform.
• Shanghai Pharmaceuticals Holding: Major Chinese pharmaceutical manufacturer and distributor with extensive hospital and retail channel reach; comparable to Coree's combined pharma distribution and manufacturing footprint, though at larger scale and with a broader branded-generic portfolio.
• China Traditional Chinese Medicine Holdings: Vertically integrated Chinese pharma group combining manufacturing, distribution, and retail pharmacy operations; directly analogous to Coree's pharma-distribution-plus-OEM model, but with a stronger bias toward traditional Chinese medicine categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/coree-llc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about COREE